Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Paroxetine mesylate
Drug ID BADD_D01683
Description Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others.[T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters.[A31914] Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class.[A31914] The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Indications and Usage Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder.[L3358] One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause.[L7703] Off-label, paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome (IBS).[A1093,A181754,A181904]
Marketing Status approved; investigational
ATC Code N06AB05
DrugBank ID DB00715
KEGG ID D05375
MeSH ID D017374
PubChem ID 9845306
TTD Drug ID D06GDY
NDC Product Code 54766-201; 62350-0074; 46014-1125; 54766-204; 46014-1097; 54766-202; 54766-203
UNII M711N184JE
Synonyms Paroxetine | Aropax | BRL-29060 | BRL 29060 | BRL29060 | FG-7051 | FG 7051 | FG7051 | Paroxetine Acetate | Seroxat | Paroxetine Hydrochloride Anhydrous | Paroxetine Maleate | Paroxetine, cis-(+)-Isomer | Paroxetine, cis-(-)-Isomer | Paroxetine, trans-(+)-Isomer | Paxil | Paroxetine Hydrochloride Hemihydrate | Paroxetine Hydrochloride, Hemihydrate | Paroxetine Hydrochloride
Chemical Information
Molecular Formula C20H24FNO6S
CAS Registry Number 217797-14-3
SMILES CS(=O)(=O)O.C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
Mydriasis17.02.11.003; 06.05.03.004--Not Available
Myelitis17.06.02.001; 11.01.03.007--
Myocardial infarction02.02.02.007; 24.04.04.009--
Myocardial ischaemia24.04.04.010; 02.02.02.008--Not Available
Myoclonus17.02.05.008--Not Available
Myopathy15.05.05.001--Not Available
Myositis15.05.01.001--
Nausea07.01.07.001--
Neck pain15.03.04.009--
Nephritis20.05.02.001--Not Available
Nephrolithiasis20.04.01.002--
Nervousness19.06.02.003--Not Available
Neuralgia17.02.07.005--
Neuropathy peripheral17.09.03.003--Not Available
Neurosis19.06.01.001--Not Available
Night blindness06.02.10.010; 14.12.03.001--
Nocturia20.02.03.001--Not Available
Nodal arrhythmia02.03.03.020--Not Available
Normochromic normocytic anaemia01.03.02.005--Not Available
Nystagmus17.02.02.006; 06.05.02.006--
Oculogyric crisis17.01.03.002; 06.05.02.002--Not Available
Oedema08.01.07.006; 14.05.06.010--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Oesophagitis07.08.05.001--
Oliguria20.01.03.004--Not Available
Optic neuritis17.04.05.001; 06.04.08.002; 10.02.01.097--Not Available
Orgasm abnormal21.03.02.013; 19.08.01.004--
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 13 Pages